Cargando…

Risk prediction of recurrent venous thrombosis; where are we now and what can we add?

BACKGROUND: Several models are available to predict recurrent venous thrombosis (VT) in patients with unprovoked first events. OBJECTIVES: To validate these prediction models externally. METHODS: Within the MEGA follow‐up study (n = 3750), we externally validated the Vienna and DASH score. These mod...

Descripción completa

Detalles Bibliográficos
Autores principales:	Timp, Jasmijn F., Lijfering, Willem M., Rosendaal, Frits R., le Cessie, Saskia, Cannegieter, Suzanne C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	THROMBOSIS
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6851549/ https://www.ncbi.nlm.nih.gov/pubmed/31188515 http://dx.doi.org/10.1111/jth.14535

Ejemplares similares

Predicting the risk of recurrent venous thrombosis: What the future might bring
por: Lijfering, Willem M., et al.
Publicado: (2019)

The joint effect of genetic risk factors and different types of combined oral contraceptives on venous thrombosis risk
por: Khialani, Deeksha, et al.
Publicado: (2020)

Procoagulant factors and future risk of arterial cardiovascular disease in patients with prior venous thrombosis: A cohort study
por: Yap, Eng Soo, et al.
Publicado: (2023)

Prediction of recurrent venous thrombosis in all patients with a first venous thrombotic event: The Leiden Thrombosis Recurrence Risk Prediction model (L-TRRiP)
por: Timp, Jasmijn F., et al.
Publicado: (2019)

Correction: Prediction of recurrent venous thrombosis in all patients with a first venous thrombotic event: The Leiden Thrombosis Recurrence Risk Prediction model (L-TRRiP)
por: Timp, Jasmijn F., et al.
Publicado: (2021)

Glucocorticoid use and risk of first and recurrent venous thromboembolism: self‐controlled case‐series and cohort study
por: Orsi, Fernanda A., et al.
Publicado: (2021)

Glucose levels and diabetes are not associated with the risk of venous thrombosis: results from the MEGA case‐control study
por: Li‐Gao, Ruifang, et al.
Publicado: (2018)

Factor V levels and risk of venous thrombosis: The MEGA case‐control study
por: Rietveld, Inge M., et al.
Publicado: (2018)

Targeted proteomics for evaluating risk of venous thrombosis following traumatic lower‐leg injury or knee arthroscopy
por: Mohammed, Yassene, et al.
Publicado: (2022)

Procoagulant factor levels and risk of venous thrombosis in the elderly
por: Wang, Huijie, et al.
Publicado: (2020)

Statin use and risk of recurrent venous thrombosis: results from the MEGA follow‐up study
por: Brækkan, Sigrid K., et al.
Publicado: (2017)

Lipid levels and risk of venous thrombosis: results from the MEGA-study
por: Morelli, Vânia M., et al.
Publicado: (2017)

Risk and Risk Factors Associated With Recurrent Venous Thromboembolism Following Surgery in Patients With History of Venous Thromboembolism
por: Nemeth, Banne, et al.
Publicado: (2019)

Rosuvastatin use reduces thrombin generation potential in patients with venous thromboembolism: a randomized controlled trial
por: Orsi, Fernanda A., et al.
Publicado: (2019)

Endogenous sex hormones and risk of venous thromboembolism in young women
por: Scheres, Luuk J. J., et al.
Publicado: (2019)

Survival after cancer-related venous thrombosis: the Scandinavian Thrombosis and Cancer Study
por: Crobach, Monique J. T., et al.
Publicado: (2023)

Switching from vitamin K antagonists to direct oral anticoagulants: Treatment satisfaction and patient concerns
por: Toorop, Myrthe M. A., et al.
Publicado: (2020)

Nutrition and venous thrombosis: An exercise in thinking about survivor bias
por: Lijfering, Willem M., et al.
Publicado: (2018)

Persistence of oral anticoagulant treatment for atrial fibrillation in the Netherlands: A surveillance study
por: Zielinski, Gilda Denise, et al.
Publicado: (2019)

Pathophysiology, risk, diagnosis, and management of venous thrombosis in space: where are we now?
por: Harris, Katie M., et al.
Publicado: (2023)

Model‐dependent contributions of FXII and FXI to venous thrombosis in mice
por: Grover, Steven P., et al.
Publicado: (2020)

Measurement of coagulation factors during rivaroxaban and apixaban treatment: Results from two crossover trials
por: Scheres, Luuk J. J., et al.
Publicado: (2018)

Venous thrombosis risk during and after medical and surgical hospitalizations: The medical inpatient thrombosis and hemostasis (MITH) study
por: Jordan Bruno, Ximena, et al.
Publicado: (2022)

Biomarkers, menopausal hormone therapy and risk of venous thrombosis: The Women's Health Initiative
por: Cushman, Mary, et al.
Publicado: (2018)

Current and future burden of venous thrombosis: Not simply predictable
por: Scheres, Luuk J. J., et al.
Publicado: (2018)

Where are we now and where are we headed?
por: Langan, Ewan A.
Publicado: (2023)

Where are we now?
Publicado: (1977)

The Absolute Risk of Venous Thrombosis after Air Travel: A Cohort Study of 8,755 Employees of International Organisations
por: Kuipers, Saskia, et al.
Publicado: (2007)

Postinterventional antithrombotic management after venous stenting of the iliofemoral tract in acute and chronic thrombosis: A systematic review
por: Notten, Pascale, et al.
Publicado: (2021)

SLC44A2 deficient mice have a reduced response in stenosis but not in hypercoagulability driven venous thrombosis
por: Tilburg, Julia, et al.
Publicado: (2020)

The Khorana score and venous and arterial thrombosis in patients with cancer treated with immune checkpoint inhibitors: A Danish cohort study
por: Overvad, Thure F., et al.
Publicado: (2022)

Awareness of venous thromboembolism among patients with cancer: Preliminary findings from a global initiative for World Thrombosis Day
por: Potere, Nicola, et al.
Publicado: (2022)

AI in medicine: Where are we now and where are we going?
por: Shandhi, Md Mobashir Hasan, et al.
Publicado: (2022)

Intrahepatic Cholangiocarcinoma—Where Are We Now and Where Are We Going to?
por: Wasilewicz, Michał P., et al.
Publicado: (2023)

Health in All policies: what do we mean and where are we now?
por: Green, L
Publicado: (2022)

NIPPV: Where Are We Now?
por: Fakharian, Atefeh, et al.
Publicado: (2013)

Onchodermatitis: Where Are We Now?
por: Murdoch, Michele E.
Publicado: (2018)

Vesicoureteral Reflux: Where Have We Been, Where Are We Now, and Where Are We Going?
por: McLorie, Gordon A.
Publicado: (2008)

Growth differentiation factor‐15 for prediction of bleeding in cancer patients
por: Mulder, Frits I., et al.
Publicado: (2021)

Coagulation factors II, V, VII, IX, X and XI and mortality – a cohort study
por: Yap, Eng Soo, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_m2d0rs79r4bimmbqh7g32rc5v5